P021: a CNTF-derived peptide studied in Alzheimer’s mouse models

Neurotrophic factors such as CNTF and BDNF support neuronal survival and plasticity. They are large proteins with short half-lives and poor blood–brain barrier penetration, which makes them hard to use as experimental tools in vivo. Researchers at the New York State Institute for Basic Research, in the laboratory of Khalid Iqbal, screened short CNTF-derived sequences. They identified an active region and capped it with an adamantylated glycine, producing compounds that include Peptide 6 and P021.

In normal adult mice and rats, P021 was associated with increased dentate gyrus neurogenesis and higher expression of synaptic markers, with spatial learning tasks used as behavioral readouts.

In the triple-transgenic (3xTg-AD) mouse model of Alzheimer’s disease, the compound was mixed into the diet, and investigators reported lower tau hyperphosphorylation and amyloid-β pathology alongside differences in behavioral tests (Kazim et al., Neurobiology of Disease, 2014). Proposed mechanisms include increased BDNF transcription and reduced GSK-3β activity, a kinase implicated in tau phosphorylation.

Almost all published P021 data come from one research group, and the compound has not been widely replicated. Its precise molecular target remains unclear. A competitive interaction with leukemia inhibitory factor (LIF) signaling has been proposed but not definitively established. Studies in additional disease models, and pharmacokinetic work in the brain, would help clarify its usefulness as a research tool.